Details of the Drug Combination

General Information of Drug Combination (ID: DCBU8D8)

Drug Combination Name
Vancomycin Moxifloxacin
Indication
Disease Entry Status REF
Peritoneal Dialysis Associated Peritonitis Phase 1 [1]
Component Drugs Vancomycin   DM3JFIH Moxifloxacin   DMU8V4S
N.A. Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Vancomycin
Disease Entry ICD 11 Status REF
Bacteremia 1A73 Approved [2]
Bacterial endocarditis N.A. Approved [2]
Clostridioides difficile infection 1A04 Approved [2]
Methicillin-resistant staphylococci infection 1A00-1A09 Approved [3]
Neonatal sepsis N.A. Approved [2]
Staphylococcal pneumonia N.A. Approved [2]
Staphylococcus aureus infection N.A. Approved [2]
MRSA infection 1D01.0Y Investigative [4]
Skin infection 1F28-1G0Z Investigative [2]
Vancomycin Interacts with 14 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
VanA ligase (vanA) DEOFMQ7 Q0WYK7_ENTFL Metabolism [7]
VanA ligase (vanA) DEO97D6 VANA_ENTFC Metabolism [7]
VanB ligase (vanB) DE27YVU Q58F99_ENTFC Metabolism [7]
VanC2 ligase (vanC) DEIF4P9 VANC_ENTGA Metabolism [8]
VanG ligase (vanG) DEPH3S7 A0A076ZC24_STRAP Metabolism [9]
VanA ligase (vanA) DEO8E75 A0A437UFE2_ENTAV Metabolism [7]
VanB ligase (vanB) DER7KFQ VANB_ENTFA Metabolism [7]
VanC2 ligase (vanC) DEH73ZC Q47720_ENTCA Metabolism [10]
D-alanylalanine synthetase (ddl) DE035GU A0A1Q6S944_9FIRM Metabolism [9]
VanG ligase (vanG) DEPN8F9 A0A076YRI6_STRAG Metabolism [9]
VanB ligase (vanB) DEMDEJ8 Q58F99_ENTFC Metabolism [11]
VanB ligase (vanB) DE2GMEK Q58F99_ENTFC Metabolism [11]
VanA ligase (vanA) DEN6VO0 A0A376GZ73_ENTGA Metabolism [12]
VanA ligase (vanA) DESOXHP A0A4U9YK96_ENTCA Metabolism [13], [12]
------------------------------------------------------------------------------------
⏷ Show the Full List of 14 DME(s)
Vancomycin Interacts with 4 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
HLA class I histocompatibility antigen, B alpha chain (HLA-B) OTNXFWY2 HLAB_HUMAN Affects Expression [14]
C-reactive protein (CRP) OT0RFT8F CRP_HUMAN Decreases Expression [15]
HLA class II histocompatibility antigen, DM beta chain (HLA-DMB) OT17HGXJ DMB_HUMAN Affects Expression [14]
Major histocompatibility complex class I-related gene protein (MR1) OTZU3XX7 HMR1_HUMAN Affects Expression [14]
------------------------------------------------------------------------------------
Indication(s) of Moxifloxacin
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [5]
Mycoplasma pneumoniae pneumonia N.A. Approved [6]
Peritonitis N.A. Approved [6]
Pneumonic plague N.A. Approved [6]
Septicemic plague N.A. Approved [6]
Staphylococcal pneumonia N.A. Approved [6]
Staphylococcus aureus infection N.A. Approved [6]
Streptococcal pneumonia N.A. Approved [6]
Tuberculosis 1B10-1B14 Approved [6]
Pneumonia caused by chlamydia N.A. Investigative [6]
Pneumonia due to Klebsiella pneumoniae CA40.03 Investigative [6]
Moxifloxacin Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU; GYRB_STAAU Modulator [16]
Staphylococcus Topoisomerase IV (Stap-coc parC) TTIXTO3 PARC_STAAS Modulator [16]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02787057) Vancomycin Plus Moxifloxacin Versus Vancomycin Plus Ceftazidime for the Treatment of Peritoneal Dialysis (PD)-Related Peritonitis
2 Vancomycin FDA Label
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
5 Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
6 Moxifloxacin FDA Label
7 Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 1993 Aug;37(8):1563-71.
8 Sequence of the vanC gene of Enterococcus gallinarum BM4174 encoding a D-alanine:D-alanine ligase-related protein necessary for vancomycin resistance. Gene. 1992 Mar 1;112(1):53-8.
9 vanG element insertions within a conserved chromosomal site conferring vancomycin resistance to Streptococcus agalactiae and Streptococcus anginosus. mBio. 2014 Jul 22;5(4):e01386-14.
10 Bacterial resistance to vancomycin: overproduction, purification, and characterization of VanC2 from Enterococcus casseliflavus as a D-Ala-D-Ser ligase. Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10040-4.
11 vanI: a novel D-Ala-D-Lac vancomycin resistance gene cluster found in Desulfitobacterium hafniense. Microb Biotechnol. 2014 Sep;7(5):456-66.
12 Emergence of high-level resistance to glycopeptides in Enterococcus gallinarum and Enterococcus casseliflavus. Antimicrob Agents Chemother. 1994 Jul;38(7):1675-7.
13 vanA in Enterococcus faecium, Enterococcus faecalis, and Enterococcus casseliflavus detected in French cattle. Foodborne Pathog Dis. 2009 Nov;6(9):1107-11.
14 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
15 [Successful treatment of MRSA-associated glomerulonephritis with antibiotic therapy]. Nihon Jinzo Gakkai Shi. 2003;45(1):37-41.
16 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.